Loading
In the first completed immunotherapy trial for anal cancer, the PD-1 antibody nivolumab shrank tumours in a quarter of heavily pretreated patients with few side effects.
Multicentre single-arm phase 2 trial: 37 patients with previously treated metastatic squamous cell carcinoma of the anal canal received nivolumab 3 mg/kg every two weeks.
Nine patients (24 percent, 95% CI 15 to 33) responded, two completely and seven partially. Grade 3 adverse events were anaemia (2), fatigue, rash and hypothyroidism (1 each); there were no serious adverse events.
PD-1 blockade is an option for metastatic anal cancer after chemotherapy, and the basis for later immunotherapy combinations in the disease.
Shares NCI9673, Metastatic and recurrent anal squamous cell carcinoma, Anal cancer (squamous cell carcinoma), Nivolumab.
Shares Metastatic and recurrent anal squamous cell carcinoma, Anal cancer (squamous cell carcinoma).
Shares Metastatic and recurrent anal squamous cell carcinoma, Anal cancer (squamous cell carcinoma).
Shares Metastatic and recurrent anal squamous cell carcinoma, Anal cancer (squamous cell carcinoma).
Shares Metastatic and recurrent anal squamous cell carcinoma, Anal cancer (squamous cell carcinoma).
Shares Metastatic and recurrent anal squamous cell carcinoma, Anal cancer (squamous cell carcinoma), Nivolumab.
Shares Metastatic and recurrent anal squamous cell carcinoma, Anal cancer (squamous cell carcinoma).
Shares Metastatic and recurrent anal squamous cell carcinoma, Anal cancer (squamous cell carcinoma).